# Kopran (NSE: KOPRAN) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/KOPRAN · Pivot · prices to 22 Oct 2026

Kopran (NSE: KOPRAN) closed at ₹274.00 on 22 Oct 2026, up 3.16% on the day. With a market capitalisation of ₹1,323 Cr, it ranks 1332nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - General.

At its last close the stock traded at 51.4× trailing earnings, against a return on equity of 4.9% in FY26. Over the past year the share price has risen 64.0%. Its 52-week range is ₹107.00 (30 Mar 2026) to ₹295.83 (30 Sep 2026); the last close is 7.4% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹234 Cr (+33.4% year on year) and net profit ₹19 Cr (+94.9%), on a consolidated basis. Promoters held 44.42% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹274.00 |
| Market cap | ₹1,323 Cr |
| P/E (trailing) | 51.4 |
| ROE | 4.9% (FY26) |
| ROCE | 8.0% (FY26) |
| Debt to equity | 0.29 |
| 52-week high | ₹295.83 (30 Sep 2026) |
| 52-week low | ₹107.00 (30 Mar 2026) |
| 1-year return | +64.0% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | ₹234 Cr | +33.4% | ₹19 Cr | +94.9% | ₹3.91 |
| Q3 FY26 | ₹194 Cr | +16.9% | ₹9 Cr | −10.2% | ₹1.93 |
| Q2 FY26 | ₹118 Cr | −22.2% | −₹10 Cr | −234.4% | −₹2.06 |
| Q1 FY26 | ₹138 Cr | −1.3% | ₹7 Cr | −32.9% | ₹2.01 |
| Q4 FY25 | ₹175 Cr | −5.7% | ₹10 Cr | −48.0% | ₹2.01 |
| Q3 FY25 | ₹166 Cr | +4.6% | ₹10 Cr | −34.1% | ₹2.16 |
| Q2 FY25 | ₹152 Cr | −0.7% | ₹7 Cr | −46.4% | ₹1.53 |
| Q1 FY25 | ₹139 Cr | +19.2% | ₹11 Cr | +300.7% | ₹2.30 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹630 Cr | ₹39 Cr |
| FY24 | ₹615 Cr | ₹51 Cr |
| FY23 | ₹551 Cr | ₹27 Cr |
| FY22 | ₹478 Cr | ₹61 Cr |
| FY21 | ₹492 Cr | ₹62 Cr |
| FY20 | ₹360 Cr | ₹21 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 44.42%
- Foreign institutions: 0.51%
- Domestic institutions: 0.00%
- Non-institutions: 55.06%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Amrutanjan Health Care](https://app.pivotnow.in/stock/AMRUTANJAN) | ₹496.20 | ₹1,435 Cr | 24.8 | — |
| [Jagsonpal Ser](https://app.pivotnow.in/stock/JAGSNPHARM) | ₹216.03 | ₹1,422 Cr | 34.2 | — |
| [TTK Healthcare](https://app.pivotnow.in/stock/TTKHLTCARE) | ₹994.70 | ₹1,406 Cr | 21.4 | — |
| [Fermenta Biotech](https://app.pivotnow.in/stock/FERMENTA) | ₹466.35 | ₹1,373 Cr | — | — |
| [Anlon Healthcare](https://app.pivotnow.in/stock/AHCL) | ₹24.35 | ₹1,294 Cr | 39.9 | — |
| [Shalby](https://app.pivotnow.in/stock/SHALBY) | ₹118.16 | ₹1,276 Cr | 36.5 | — |

## Questions and answers

### What is the share price of Kopran today?

Kopran (NSE: KOPRAN) last closed at ₹274.00 on 22 Oct 2026. Its 52-week high is ₹295.83 and its 52-week low is ₹107.00.

### What is the market cap of Kopran?

Kopran's market capitalisation is ₹1,323 Cr (₹1,323 Cr) at the 22 Oct 2026 close, ranking 1332nd among the NSE companies Pivot tracks.

### What is the P/E ratio of Kopran?

Kopran trades at a trailing P/E of 51.4. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 34.2.

### What is the ROE and ROCE of Kopran?

Return on equity was 4.9% in FY26 and return on capital employed was 8.0% in FY26 (consolidated figures).

### Is Kopran a debt-free company?

No. Kopran's debt-to-equity ratio was 0.29 in FY26, with total debt of ₹14 Cr.

### What were Kopran's latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Kopran reported revenue of ₹234 Cr, +33.4% year on year, and net profit of ₹19 Cr, +94.9% year on year.

### How has Kopran stock performed over the last year?

Kopran's share price has risen 64.0% over the past year, +35.6% over three months and −2.8% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Kopran?

As of 30 Jun 2026: promoters 44.42%, foreign institutions 0.51%, domestic institutions 0.00%, non-institutions 55.06%.

### Who are Kopran's competitors?

The listed Pharma & Healthcare companies closest to Kopran by market cap are Amrutanjan Health Care, Jagsonpal Ser, TTK Healthcare, Fermenta Biotech, Anlon Healthcare and Shalby.

### Is Kopran a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Kopran's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on KOPRAN against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.